Overview

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Status:
Completed
Trial end date:
2012-04-24
Target enrollment:
Participant gender:
Summary
To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc